Literature DB >> 25085855

Sevoflurane-enriched blood cardioplegia: the intramyocardial delivery of a volatile anesthetic.

A van der Baan1, K A Kortekaas2, E van Es2, S Meier3, R J M Klautz2, F H M Engbers3.   

Abstract

Myocardial ischemia/reperfusion injury is a major problem in cardiac surgery, characterized by an enhanced inflammatory response postoperatively. Sevoflurane has anti-inflammatory effects and may attenuate this injury. This study describes a novel approach to using sevoflurane as a local anti-inflammatory drug and not as an anesthetic. Therefore, a pediatric oxygenator with a sevoflurane vaporizer was integrated into the blood cardioplegia system of an adult bypass system. In addition, a gas blender was implemented to regulate pO2 and pCO2 concentrations in the cardioplegia. This proof-of-principle study was tested in vivo and shows that it is feasible to deliver sevoflurane locally while regulating O2 and CO2 concentrations. Moreover, this set-up enables one to use only the specific cardioprotective features of sevoflurane. Inflammatory responses were attenuated, both locally (i.e. the heart) as well as systemically through intramyocardial delivery of sevoflurane.
© The Author(s) 2014.

Entities:  

Keywords:  blood cardioplegia; cardiopulmonary bypass; inflammation; oxygenator; sevoflurane

Mesh:

Substances:

Year:  2014        PMID: 25085855     DOI: 10.1177/0267659114545666

Source DB:  PubMed          Journal:  Perfusion        ISSN: 0267-6591            Impact factor:   1.972


  2 in total

1.  Sevoflurane affects evoked electromyography monitoring in cerebral palsy.

Authors:  Xin Chen; Lufeng Xu; Yuanlin Wang; Feng Xu; Yemu Du; Jinyu Li
Journal:  Open Med (Wars)       Date:  2016-05-17

2.  Pre-cardiopulmonary bypass administration of dexmedetomidine decreases cardiac troponin I level following cardiac surgery with sevoflurane postconditioning.

Authors:  Hong-Mei Zhou; Xiao-Yan Ling; Yun-Jian Ni; Cheng Wu; Zhi-Peng Zhu
Journal:  J Int Med Res       Date:  2019-06-24       Impact factor: 1.671

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.